Junshi/Coherus PD-1 Meets Endpoints in US Phase III NSCLC Trial
publication date: Mar 15, 2022
Shanghai Junshi Bio's anti-PD-1 met its endpoints in a US Phase III trial for NSCLC. The double-blind Phase III trial tested toripalimab plus chemotherapy as a first-line therapy for non-small cell lung cancer. Compared to chemotherapy alone, the combination therapy showed clinically meaningful improvement in progression-free survival and overall survival. Last year, Junshi and its US partner, Coherus BioSciences of Redwood City, filed for US approval of toripalimab as a first-line treatment for advanced nasopharyngeal carcinoma. More details....
Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ: CHRS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.